Ad
MGTX Message Board | MeiraGTx Holdings plc
home / stock / mgtx / mgtx message board
Message Board | MeiraGTx Holdings plc (NASDAQ:MGTX)
| Subject | By | Source | When |
|---|---|---|---|
| must see | stockguard | investorshub | 05/02/2023 11:41:04 AM |
| $MGTX MomentumIts trading | mcp4 | investorshub | 04/25/2023 8:18:05 PM |
| $MGTX must see | mcp4 | investorshub | 04/18/2023 7:07:33 PM |
| znewcar1: MGTX 29% v7,7M c18.56 f44,3M H19.17 | znewcar1 | investorshangout | 10/18/2021 8:15:27 PM |
| MeiraGTx (NASDAQ:MGTX) Given Buy Rating at Piper Jaffray Companies | stockguard | investorshub | 12/30/2019 9:54:37 PM |
| Janssen Pharmaceuticals and MeiraGTx just entered into a | mcp4 | investorshub | 10/19/2018 5:17:08 PM |
| Zacks Investment Research downgraded $MGTX from a hold | mcp4 | investorshub | 09/10/2018 1:07:16 PM |
| Chardan Capital just rated $MGTX a Buy with | mcp4 | investorshub | 08/24/2018 5:44:35 PM |
| Some recent analyst comments on $MGTX: | mcp4 | investorshub | 08/21/2018 1:38:10 PM |
| FDA has granted orphan drug designation to MeiraGTx's | mcp4 | investorshub | 08/15/2018 6:32:59 PM |
| European Medicines Agency's (EMA) Committee gave MieraGTx a | mcp4 | investorshub | 07/03/2018 7:17:44 PM |
Stock Information
Get MGTX Alerts
News, Short Squeeze, Breakout and More Instantly...
MeiraGTx Holdings plc Company Name:
MGTX Stock Symbol:
NASDAQ Market:
1.44% G/L:
$7.56 Last:
849,485 Volume:
$7.54 Open:
$7.56 Close:
MeiraGTx Holdings plc Website:
Ad
-
Team Inc. (TISI) is expected to report for quarter end 2024-12-31 Chesswood Group Limited (CHWWQ) is expected to report for Q4 2024 J. W. Mays Inc. (MAYS) is expected to report for Q2 2025 Allakos Inc. (ALLK) is expected to report $-0.17 for Q4 2024 Aurora Mobile Limited (JG) is e...
-
2025-02-23 03:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
- RMAT designation recognizes the preliminary clinical evidence of the potential benefit of AAV2-hAQP1 as a one-time treatment for this debilitating condition - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy designations, allows frequent regu...